Undisclosed target (Shengeke Biotech)

This entry refers to a proprietary protein target currently under investigation by Shengeke Biotech (Shanghai Shengeke Pharmaceutical Technology) using Proteolysis Targeting Chimera (PROTAC) technology. PROTACs are a class of bifunctional molecules that facilitate the degradation of specific proteins by hijacking the cell's natural protein disposal system, the ubiquitin-proteasome pathway (Bekes et al., 2022, Nature Reviews Drug Discovery). By recruiting an E3 ubiquitin ligase to the protein of interest, these molecules induce polyubiquitination and subsequent proteasomal degradation (Sun et al., 2019, Signal Transduction and Targeted Therapy). Because the specific identity of this target has not been disclosed in public pipeline records or scientific literature provided by Shengeke Biotech, its precise biological functions and molecular classifications remain unknown (Shengeke Biotech Official Website, 2024). Typically, such undisclosed targets in the PROTAC space are selected for their roles in driving cancer progression or other complex diseases where traditional small-molecule inhibitors have failed to provide adequate therapeutic benefit. Without a disclosed name or structure, detailed pharmacological profiles and specific safety concerns cannot be established for this particular molecule.

Other names

Unknown protein of interestShengeke undisclosed PROTAC targetUndisclosed Shengeke protein

Targeted protein degradation via Proteolysis Targeting Chimera (PROTAC) technology